BPIQ Blog

Feb 24, 20191 min read

Roche close to buying ONCE according to WSJ

In case you missed our posts on Linked-In and Twitter yesterday, the Wall Street Journal is reporting big news in gene therapy and...

Feb 19, 20192 min read

ICPT Ocaliva Phase 3 Readout

An important readout occurred today in the very hot pharmaceutical development area called NASH, a severe fatty liver disease. NASH is...

Feb 11, 20192 min read

Amp Mid-Q1 '19 Update

We are thrilled to report that our Amp Core hypothetical fund is off to a tremendous start in 2019. This fund is up around 13% since the...

Jan 21, 20192 min read

Cara Therapeutics - Itching For Big Returns In 2019

Summary CARA's switch from pain to pruritis (chronic severe itching) is a sound strategy as the pruritis data and market provide a much...

Nov 30, 20182 min read

Amarin's U.S. Patent Protection For Vascepa

Download Full Article Summary Amarin has patent protection for Vascepa® out to 2030, including protection related to the possible...

Oct 31, 20181 min read

ALKS Amp Update & Upcoming Catalysts

10/31/18 Amp cut its positions in ALKS in various AMP funds today by 1/2 after careful review of FDA briefing document for tomorrow's FDA...

Oct 30, 20181 min read

Upcoming Catalysts On The Radar: ARQL & GBT

ASH abstracts coming 12/1. Looking forward to $ARQL update on reversible Btk inhib ARQ 531 for C481S mutants (Ibrutinib resistance) in B...

Oct 23, 20181 min read

SELB 5-Month Data Update

SEL-212 data looks good thru 5 months, and therapy appears more likely approvable with future phase 3 trial, but data not exceptional...

Oct 9, 20181 min read

Keep Your Eyes on Clearside

Amp funds are invested in a small percentage in CLSD currently (as of 10/6/18). We like the next-gen ocular steroid platform and the...

Sep 28, 20182 min read

Tocagen's Promising Glioblastoma Therapy

John McCain died of glioblastoma last month. My father died of glioblastoma back in the 1970s when he was around 40 years old. Currently,...

Sep 25, 20182 min read

Congrats Amarin for Major Breakthrough in Treating Cardiovascular Disease

Yesterday, Amarin (AMRN) reported top-line results from a landmark Phase 3 study which showed that their product called Vascepa reduced...

Aug 7, 20181 min read

Key Readout Fast Approaching for FOMX

Looking at available information, it is likely that FOMX will read out its pivotal repeat phase 3 trial of FMX101 for acne some time...

Jul 24, 20183 min read

Amp Up July 2018

Amp's exciting news, and best upcoming biotech picks

Jul 15, 20181 min read

TBPH To Report On nOH Results For TD-9855 This Month - Medium Risk And Reward

Summary TBPH reporting TD-9855 data in nOH by end of July Medium risk and reward opportunity TBPH July data for wholly owned TD-9855...

Jul 14, 20181 min read

Congrats to ZGNX on More Positive Data

Second Phase 3 study of ZX008 in Dravet's met primary and all key second endpoints. Data for ZX008 in Dravet continues to look very good...

Jul 14, 20181 min read

CBIO 1st Efficacy Results For MarzAA In HemA This Week

First efficacy data readout coming on July 18, 2018 for MarzAA. High risk event, but encouraging that press release indicates...

Jul 1, 20181 min read

ZGNX imminently releasing more Ph3 data in a severe form of childhood epilepsy

Zogenix (ZGNX) is set to imminently release additional phase 3 data from its trial with its drug ZX008 (low dose fenfluramine) for...

Jun 23, 20181 min read

GBT's Part A Phase 3 Sickle Cell Data - Any Day Now

Looking forward to Global Blood Therapeutics report out of Part A from their Phase 3 Hope study of their drug voxelotor (formerly GBT440)...

Jun 23, 20181 min read

ARRY presents excellent updated CRC data at WorldGI2018

Congrats Array Biopharma on continued excellent data on its colorectal cancer (CRC) study of patients with BRAF V600E mutations with the...

Jun 19, 20181 min read

Busy Rest of June for ARRY

It will be an exciting rest of June for Array Biopharma (ARRY) with 2 PDUFAs (final FDA drug approvals) for its 2 lead drug candidates...

Jump start your biotech due diligence

Get started →

Our platform helps you uncover your next biotech investment opportunity